| Literature DB >> 21267813 |
Abstract
Paraneoplastic syndromes occur in approximately 10% of all patients with lung cancer. They can be the first manifestation of the disease or of a recurrence. Endocrine, haematological, neuromuscular, dermatological, renal, and metabolic syndromes as well as syndromes involving the connective tissue and constitutional syndromes can be distinguished based on their clinical symptoms. In this review, the epidemiology, pathogenesis, clinical signs and treatment options for the clinically important paraneoplastic syndromes in lung cancer are discussed. © Georg Thieme Verlag KG Stuttgart · New York.Entities:
Mesh:
Year: 2011 PMID: 21267813 DOI: 10.1055/s-0030-1256118
Source DB: PubMed Journal: Pneumologie ISSN: 0934-8387